Physician profile
Alla Khalfin
NPI 1528259843
$48,233.04
in general payments reported to CMS, 2019-2025
61 companies · $3,499 in 2025
The $3,499 reported for 2025 was more than what 85% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $6,403 · 2021: $2,664 · 2022: $4,342 · 2023: $10K · 2024: $9,221 · 2025: $3,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $5,971 · Education: $2,869 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,795 · Travel and Lodging: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,492.45 |
| Consulting Fee | $5,970.75 |
| Education | $2,869.26 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,795.00 |
| Travel and Lodging | $854.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $10,860.68 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $8,870.21 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $6,243.66 | 2019-2025 | Unithroid |
| Corcept Therapeutics | $4,216.45 | 2019-2025 | Korlym |
| Novo Nordisk INC | $2,168.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,973.44 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $1,722.95 | 2019-2025 | Evenity, Tepezza, Prolia |
| Lilly USA, LLC | $1,709.26 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Xeris Pharmaceuticals, INC. | $1,199.28 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Abbvie INC. | $946.25 | 2019-2025 | |
| Radius Health, INC. | $852.11 | 2019-2025 | Tymlos |
| Mannkind Corporation | $826.05 | 2019-2024 | Afrezza |
| Dexcom, INC. | $717.17 | 2022-2025 | Dexcom G6 Transmitter |
| Vivus LLC | $498.83 | 2019-2025 | Qsymia |
| Abbott Laboratories | $498.24 | 2019-2025 | Freestyle Libre 3 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $485.31 | 2019-2024 | Omnipod |
| Merck Sharp & Dohme LLC | $421.25 | 2019-2023 | Steglujan, Steglatro, Belsomra |
| Senseonics, Incorporated | $400.00 | 2019 | |
| Ibsa Pharma INC. | $314.10 | 2021-2025 | Tirosint, Licart, Flector |
| Horizon Therapeutics Plc | $305.51 | 2019-2023 | Tepezza |
| Endo Pharmaceuticals INC. | $286.13 | 2020-2023 | Aveed, Edex |
| Currax Pharmaceuticals LLC | $226.64 | 2020-2025 | Contrave, Nexletol |
| Amarin Pharma, INC. | $223.10 | 2019-2022 | |
| Medtronic, INC. | $220.78 | 2021-2024 | Minimed 780g, Minimed 770g |
| Astellas Pharma US INC | $197.96 | 2024-2025 | Veozah |
| Esperion Therapeutics, INC. | $169.59 | 2022-2025 | Nexletol |
| Tandem Diabetes Care, INC. | $162.41 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.55 | 2022-2024 | Cycloset |
| Alexion Pharmaceuticals, INC. | $101.06 | 2023-2025 | Strensiq |
| Urovant Sciences INC | $99.67 | 2022 | |
| Eisai INC. | $96.53 | 2019 | |
| Ascendis Pharma Endocrinology INC | $86.79 | 2025 | Yorvipath |
| Recordati_rare_diseases_inc. | $70.15 | 2025 | Isturisa |
| Tolmar, INC. | $68.22 | 2024 | |
| Renalytix Ai, INC. | $66.71 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Vistapharm, INC. | $57.22 | 2021 | |
| Intra-Sana Laboratories | $55.14 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Janssen Pharmaceuticals, INC | $55.06 | 2019-2021 | |
| Beta Bionics, INC. | $46.61 | 2024 | Ilet Bionic Pancreas |
| Medtronic Minimed, INC. | $45.47 | 2020 | |
| Ascensia Diabetes Care US INC. | $44.51 | 2021-2025 | |
| Verity Pharmaceuticals INC. | $44.17 | 2024-2025 | Tlando |
| Amryt Pharma Holdings LTD | $40.01 | 2022 | |
| Acella Pharmaceuticals, LLC | $37.13 | 2023-2025 | NP Thyroid 60 |
| Cequr Corporation | $36.57 | 2023 | Cequr Simplicity |
| Clarus Therapeutics INC. | $31.72 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.27 | 2024 | |
| Averitas Pharma INC. | $30.16 | 2025 | Qutenza |
| Antares Pharma, INC. | $29.95 | 2020-2022 | |
| Sequel Med Tech, LLC | $26.80 | 2025 | Twiist |
| Almatica Pharma LLC | $26.74 | 2025 | Teriparatide |
| Sumitomo Pharma America, INC. | $26.73 | 2024 | Gemtesa |
| Lifescan, INC. | $24.12 | 2021 | |
| Shire North American Group INC | $21.94 | 2019 | |
| Glaxosmithkline, LLC. | $18.83 | 2025 | Arexvy, Shingrix |
| Azurity Pharmaceuticals, INC. | $18.36 | 2023 | Adthyza |
| Gilead Sciences, INC. | $16.20 | 2019 | |
| Acerus Pharmaceuticals Corporation | $15.76 | 2020 | |
| Echosens North America, INC. | $15.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.94 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alla Khalfin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.